Previous 10 | Next 10 |
DUBLIN , Nov. 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer's (SITC) 34 th Annual Meeting in National Harbor, MD. ALKS 4230 is an...
– Supplemental Materials Will be Made Available on Alkermes' Website on Friday, Nov. 8 – DUBLIN , Nov. 4, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from its ARTISTRY clinical development program rel...
The FDA approves Biogen's (NASDAQ: BIIB ) Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. More news on: Biogen Inc., Alkermes plc, ...
CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY ™ (diroximel fumarate), a novel oral fumarate with a distinct...
Alkermes plc (ALKS) Q3 2019 Results Earnings Conference Call October 23, 2019, 08:00 AM ET Company Participants Sandra Coombs - Vice President, Investor Relations Richard Pops - Chairman and Chief Executive Officer James Frates - Senior Vice President and Chief Financial Officer ...
Image source: The Motley Fool. Alkermes PLC (NASDAQ: ALKS) Q3 2019 Earnings Call Oct 23, 2019 , 8:00 a.m. ET Operator Continue reading
Alkermes ( ALKS ) Q3 results : Revenues: $255.2M (+2.6%); Vivitrol: $85.2M (+6.6%); Aristrada: $53.6M (+48.5%); Manufacturing and royalty revenues: $103.8M (-10.8%). More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
The following slide deck was published by Alkermes plc in conjunction with their 2019 Q3 earnings Read more ...
Alkermes (NASDAQ: ALKS ): Q3 Non-GAAP EPS of -$0.04 beats by $0.17 ; GAAP EPS of -$0.34 beats by $0.17 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , Oct. 23, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2019 and the implementation of a restructuring plan following a review of the company's operations, cost structure and growth opportunities. "As...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...